WO2019231443A1 - Marker and method for evaluating cognitive dysfunction - Google Patents

Marker and method for evaluating cognitive dysfunction Download PDF

Info

Publication number
WO2019231443A1
WO2019231443A1 PCT/US2018/035224 US2018035224W WO2019231443A1 WO 2019231443 A1 WO2019231443 A1 WO 2019231443A1 US 2018035224 W US2018035224 W US 2018035224W WO 2019231443 A1 WO2019231443 A1 WO 2019231443A1
Authority
WO
WIPO (PCT)
Prior art keywords
subject
blood
cognitive dysfunction
concentration
led light
Prior art date
Application number
PCT/US2018/035224
Other languages
French (fr)
Inventor
Wan-lin WU
Sun CHIA-WEI
Chun-Jung Huang
Che-Wei Chen
Chuan-Hsiang YU
Ting-ying LI
Original Assignee
Chi-Hua Foundation
WU, Tiffany
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chi-Hua Foundation, WU, Tiffany filed Critical Chi-Hua Foundation
Priority to PCT/US2018/035224 priority Critical patent/WO2019231443A1/en
Publication of WO2019231443A1 publication Critical patent/WO2019231443A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14542—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring blood gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/024—Detecting, measuring or recording pulse rate or heart rate
    • A61B5/02416—Detecting, measuring or recording pulse rate or heart rate using photoplethysmograph signals, e.g. generated by infrared radiation
    • A61B5/02427—Details of sensor
    • A61B5/02433—Details of sensor for infrared radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
    • A61B5/165—Evaluating the state of mind, e.g. depression, anxiety
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4058—Detecting, measuring or recording for evaluating the nervous system for evaluating the central nervous system
    • A61B5/4064—Evaluating the brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A61B5/4088—Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
    • A61B5/6813—Specially adapted to be attached to a specific body part
    • A61B5/6814—Head
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/04—Arrangements of multiple sensors of the same type
    • A61B2562/043—Arrangements of multiple sensors of the same type in a linear array

Definitions

  • the invention relates to a marker and a method for evaluating cognitive dysfunction, particularly to evaluating cognitive dysfunction through the concentration variation of oxygenated blood and hypoxic blood via a near-infrared device.
  • dementia With the rapid ageing of the population in the modern society, the number of people with dementia increases rapidly. However, dementia has never been cured, and care of dementia has become a heavy familial and social burden. Despite no therapy for curing dementia in nowadays, some drugs have been provided for alleviating deterioration in the early stages of the disease. Therefore, it is an important issue to detect dementia in early stage.
  • Dementia can be divided into two major types as degenerative dementia and vascular dementia according to the cause of brain lesions.
  • the former is due to the degeneration of neural cell body, while the latter is due to cerebrovascular infarction or hemorrhage that lead to insufficient blood supplying and brain cells death, and further led to mental decline.
  • these two types of dementia often exist in combination.
  • stroke patients may suffer dementia with the probability of about 20% to 40% within five years. No matter what type of stroke, as long as the number of strokes or the area of damage is large enough, it may lead to dementia or aggravate the existing dementia.
  • Infrared spectroscopy is a kind of traditional optical technology that can monitor the variation of blood oxygen in tissues.
  • the characteristics of different substances in the tissue have different absorption coefficients (p a ).
  • NIRS near-infrared spectroscopy
  • NIRS is a non-invasive optical detection method and is commonly used to monitor brain blood oxygenation variation and to quantify tissue functional parameters.
  • Mild cognitive dysfunction refers to a cognitive function disorder between dementia and mental retardation. The patient is well in daily life activities, but the extent of memory declines to under-normal standards.
  • scale tests are often used as diagnostic criteria, such as the mini-mental state examination (MMSE), the Wisconsin card sorting test (WCST), cognitive abilities screening instrument (CASI) and the clinical dementia rating (CDR). These tests are used to detect the subject's concentration ability and executive function, particularly to the subjects who are tested through external stimuli to convert decision-making skills.
  • the Wisconsin card sorting test has a high sensitivity for the subjects with“prefrontal lobe damaged”. In addition, due to the prefrontal lobe is affected by aging more rapidly than other areas of the brain, the Wisconsin card sorting test is also commonly used in brain aging research.
  • NVC response neurovascular coupling response
  • An objective of the present invention is to provide a method for evaluating cognitive dysfunction in which the method can be used to diagnose whether a patient has cognitive dysfunction.
  • the method for evaluating cognitive dysfunction of the present invention comprising following steps:
  • Step 1 Attaching a near-infrared spectroscopy device to a subject's brain's prefrontal lobe;
  • Step 2 Closing the subject’s eyes and relaxing for 1 minute as a reference value in blood oxygen variation; Step 3: Conducting an external stimulus test to the subject;
  • Step 4 Closing the subject’s eyes again and relaxing for 2 minutes to complete the test
  • Step 5 Transmitting a blood oxygen variation signal from the near-infrared spectroscopy device attached the subject's brain's prefrontal lobe via a wired or wireless method to operation unit for data storage and analysis;
  • Step 6 After the external stimulus test, if the concentrations of the oxygenated and hypoxic blood are both increased in the left and right prefrontal lobes, the patient will be diagnosed as with cognitive dysfunction.
  • the above evaluation method is simple, fast, and time-saving, and does not require the subject to do too many difficult tests. After the subject completes the foregoing steps, the subject or its family can save the waiting time due to the results can be generated immediately.
  • the method of the present invention can achieve early detection and earlier treatment effects via a rapid diagnosis.
  • Another objective of the present invention is to provide a marker for evaluating cognitive dysfunction, wherein the marker can diagnose dementia in a subject in early stage.
  • the marker for evaluating cognitive dysfunction of the present invention comprises the detection of blood oxygen variation signal in the prefrontal lobe of the stimulated subject through the near-infrared spectroscopy device. While the concentration of the oxygenated blood and the hypoxic blood are both increased, it means that the left and the right prefrontal lobes responsible for cognition are both damaged, and the subject suffers cognitive dysfunction.
  • FIG. l is a schematic diagram of the present invention.
  • FIG.2 is a schematic diagram of the near-infrared spectroscopy device of the present invention.
  • FIG. 3 is a schematic diagram of a position for attaching a near-infrared spectroscopy device of the present invention.
  • FIG. 4 is a result of the variation of the oxygenated blood of the present invention.
  • FIG. 5 is a result of the variation of the hypoxic blood of the present invention.
  • a mini-mental state examination (referred to as "WCST" in this embodiment) was used as a stimulus to the subject's brain, and the oxygenated blood concentration variation in the left and the right prefrontal lobe was detected by the near-infrared spectroscopy.
  • MMSE mini-mental state examination
  • a near-infrared spectroscopy device 30 was attached to a brain of a subject 20, wherein the near-infrared spectroscopy device 30 had multiple pairs of LED light source 31 with different emission near-infrared wavelengths and a light sensor 32.
  • the light sources 31 was faced onto the forehead of the subject 20 (referring to the positions of Fql and Fq2 shown in FIG. 3), and then the variation of blood oxygen concentration in the left prefrontal lobe and the right prefrontal lobe could be measured and generated a blood oxygen concentration variation signal 33.
  • the blood oxygen concentration variation signal 33 was then transmitted to an operation unit 40 for data storage and analysis through a wired or wireless connection via the light sensor 32, wherein the sampling frequency could be set up to 50 Hz.
  • the LED light sources 31 were three pairs, and each pair of LED light sources 31 could emit two different wavelengths of near-infrared light.
  • light with the wavelength from 650 nm to 950 nm is mainly absorbed by oxygenated hemoglobin and hypoxemic hemoglobin in the blood.
  • 760 nm and 850 nm wavelengths were used respectively, and the distance between the three pairs of the LED light sources 31 and the light sensors 32 were respectively 30 mm, 35 mm, and 40 mm from the inside to the outside.
  • Rest phase The subject 20 was required to close his/her eyes and relax for 1 minute as a reference value in blood oxygen variation.
  • Test stage The subject 20 was stimulated by a stimulus source 10, wherein the test time varies depending on the subject and the stimulus source.
  • the value of the blood oxygen concentration variation of each subject 20 was the blood oxygen concentration value in the test phase minus the blood oxygen concentration value in the rest phase, and the blood oxygen concentration variations in the left prefrontal lobe and the right prefrontal lobe were all recorded.
  • the concentration of the oxygenated blood was increased in subjects regardless of whether who have had a stroke or cognitive dysfunction.
  • the subjects with normal cognitive function (referred to as the control group 1) had increased oxygen consumption in the brain when stimulated, but the concentrations of hypoxic blood in both the left and right prefrontal lobes were still decreased due to the increased blood supply in reaction to the stimuli.
  • the concentrations of hypoxic blood in both the left and right prefrontal lobes were all increased. It is due to insufficient amount of the reactive blood supply increased to meet the need by stimuli.
  • the control group 2 in FIG. 5 was the subjects who had stroke but with normal cognitive function via the mini-mental state examination. In this condition, the concentration of hypoxic blood was still decreased in one of the prefrontal lobes, i.e. the increased blood supply in reaction to the stimuli remained normal in at least one of the prefrontal lobes.
  • the device could be used to evaluate the concentration variation of the oxygenated blood and the hypoxic blood in the left and right prefrontal lobes after stimulation of the subject's brain, and various parameters derived therefrom as diagnostic indicators of whether the subjects have cognitive dysfunction, and for the early detection and early treatment.
  • a marker and a method for elevating cognitive dysfunction of the present invention included: the stimulus 10, the near-infrared spectroscopy device 30, and the operation unit 40 for receiving and calculating the signal from the near-infrared spectroscopy device 30.
  • the method for evaluating cognitive dysfunction of the present invention comprised the following steps:
  • Step 1 Attaching the near-infrared spectroscopy device 30 to the subject's forehead
  • Step 2 Stimulating the subject 20 via the stimulus 10 for testing cognitive dysfunction, wherein the stimulus 10 was the Wisconsin card sorting test (WCST) in this embodiment.
  • the near-infrared spectroscopy device 30 was used to detect the concentration of blood oxygen in the prefrontal lobe of the subject, and then produces a blood oxygen variation signal 33 from the prefrontal lobe;
  • Step 3 The operation unit 40 received the blood oxygen variation signal 33 detected by the near-infrared spectroscopy device 30, and then quantizes the signal according to the concentration of oxygenated blood and hypoxic blood as a result report 50;
  • Step 4 The concentration of oxygenated blood in the result report 50 as control group. When the concentration of oxygenated blood was increased, it indicated that the operation was normal. After then, the concentration of hypoxic blood in both the left and the right prefrontal lobes were all increased, the subject was judged to suffer cognitive dysfunction (referred to FIGs 4 and 5).

Abstract

Provided are a marker and a method for evaluating mild cognitive dysfunction, which comprises: attaching a near-infrared spectroscopy device to the brain of a subject and performing an external stimulus test on the subject while the blood oxygen concentration in prefrontal lobe of the subject is detected by using the near-infrared spectroscopy. A result report is produced by analysis. For early detection and early treatment, the concentration variation of the oxygenated blood and the hypoxic blood in prefrontal lobe can be used to evaluate whether the subject suffers cognitive dysfunction.

Description

MARKER AND METHOD FOR EVALUATING COGNITIVE
DYSFUNCTION
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to a marker and a method for evaluating cognitive dysfunction, particularly to evaluating cognitive dysfunction through the concentration variation of oxygenated blood and hypoxic blood via a near-infrared device.
2. Description of the Prior Arts
With the rapid ageing of the population in the modern society, the number of people with dementia increases rapidly. However, dementia has never been cured, and care of dementia has become a heavy familial and social burden. Despite no therapy for curing dementia in nowadays, some drugs have been provided for alleviating deterioration in the early stages of the disease. Therefore, it is an important issue to detect dementia in early stage.
Dementia can be divided into two major types as degenerative dementia and vascular dementia according to the cause of brain lesions. The former is due to the degeneration of neural cell body, while the latter is due to cerebrovascular infarction or hemorrhage that lead to insufficient blood supplying and brain cells death, and further led to mental decline. However, these two types of dementia often exist in combination. According to statistics, stroke patients may suffer dementia with the probability of about 20% to 40% within five years. No matter what type of stroke, as long as the number of strokes or the area of damage is large enough, it may lead to dementia or aggravate the existing dementia. Other studies have found that patients with dementia tend to decrease functional physiologic parameters such as vascular perfusion, oxygen metabolism, etc., due to cerebrovascular damage, and vascular reactivity is considered as an important factor of dementia. In addition, the prefrontal lobe is responsible for the cognitive function and the judgment of personality. In patients with cognitive dysfunction or early dementia, their brain may have abnormal microcirculation and the vascular function in the prefrontal lobe is severely damaged. As a result, while the patient's attention and performance deteriorates, it may be diagnosed as early dementia.
Infrared spectroscopy is a kind of traditional optical technology that can monitor the variation of blood oxygen in tissues. The characteristics of different substances in the tissue have different absorption coefficients (pa). For obtaining blood oxygen variation in local tissues, near-infrared spectroscopy (NIRS) is a non-invasive optical detection method and is commonly used to monitor brain blood oxygenation variation and to quantify tissue functional parameters.
Mild cognitive dysfunction (MCI) refers to a cognitive function disorder between dementia and mental retardation. The patient is well in daily life activities, but the extent of memory declines to under-normal standards. In clinical screening for mild cognitive dysfunction, scale tests are often used as diagnostic criteria, such as the mini-mental state examination (MMSE), the Wisconsin card sorting test (WCST), cognitive abilities screening instrument (CASI) and the clinical dementia rating (CDR). These tests are used to detect the subject's concentration ability and executive function, particularly to the subjects who are tested through external stimuli to convert decision-making skills. The Wisconsin card sorting test has a high sensitivity for the subjects with“prefrontal lobe damaged”. In addition, due to the prefrontal lobe is affected by aging more rapidly than other areas of the brain, the Wisconsin card sorting test is also commonly used in brain aging research.
In recent studies, cognitive function and neurovascular coupling response (NVC response) has a high positive correlation. When neuron activation leads to increasing oxygen consumption, the blood perfusion to brain tissue will be also increased to supply the oxygen consumption and enhance the concentration of oxygenated blood through neurovascular coupling reaction. While the neurovascular coupling reaction is impaired, there will be obstacles in cognitive function. However, regardless of whether with cognitive dysfunction, the concentration of oxygenated blood will increase in the brain, so it cannot be a diagnostic test for whether the patient suffers cognitive dysfunction. SUMMARY OF THE INVENTION
An objective of the present invention is to provide a method for evaluating cognitive dysfunction in which the method can be used to diagnose whether a patient has cognitive dysfunction.
In order to achieve the objective above-mentioned, the method for evaluating cognitive dysfunction of the present invention comprising following steps:
Step 1 : Attaching a near-infrared spectroscopy device to a subject's brain's prefrontal lobe;
Step 2: Closing the subject’s eyes and relaxing for 1 minute as a reference value in blood oxygen variation; Step 3: Conducting an external stimulus test to the subject;
Step 4: Closing the subject’s eyes again and relaxing for 2 minutes to complete the test;
Step 5: Transmitting a blood oxygen variation signal from the near-infrared spectroscopy device attached the subject's brain's prefrontal lobe via a wired or wireless method to operation unit for data storage and analysis;
Step 6: After the external stimulus test, if the concentrations of the oxygenated and hypoxic blood are both increased in the left and right prefrontal lobes, the patient will be diagnosed as with cognitive dysfunction.
The above evaluation method is simple, fast, and time-saving, and does not require the subject to do too many difficult tests. After the subject completes the foregoing steps, the subject or its family can save the waiting time due to the results can be generated immediately. The method of the present invention can achieve early detection and earlier treatment effects via a rapid diagnosis.
Another objective of the present invention is to provide a marker for evaluating cognitive dysfunction, wherein the marker can diagnose dementia in a subject in early stage.
To achieve the above objective, the marker for evaluating cognitive dysfunction of the present invention comprises the detection of blood oxygen variation signal in the prefrontal lobe of the stimulated subject through the near-infrared spectroscopy device. While the concentration of the oxygenated blood and the hypoxic blood are both increased, it means that the left and the right prefrontal lobes responsible for cognition are both damaged, and the subject suffers cognitive dysfunction.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. l is a schematic diagram of the present invention.
FIG.2 is a schematic diagram of the near-infrared spectroscopy device of the present invention.
FIG. 3 is a schematic diagram of a position for attaching a near-infrared spectroscopy device of the present invention.
FIG. 4 is a result of the variation of the oxygenated blood of the present invention.
FIG. 5 is a result of the variation of the hypoxic blood of the present invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
For better understanding, the technical methods and operation process of the present invention, and examples are illustrated in conjunction with the drawings, as described in detail below.
Example 1
In an example embodiment, a mini-mental state examination (referred to as "WCST" in this embodiment) was used as a stimulus to the subject's brain, and the oxygenated blood concentration variation in the left and the right prefrontal lobe was detected by the near-infrared spectroscopy.
From the subjects’ clinical diagnosis and mini-mental state examination (MMSE), the MMSE score less than 25 points indicates that the subject suffers cognitive dysfunction. The subjects were suddivided into the following four groups: A control group 1 : subjects who have not suffered a stroke and have normal cognitive function. A control group 2: subjects who have suffered a stroke and have normal cognitive function. Experimental group 1 : subjects who have not suffered a stroke but have cognitive dysfunction. Experimental group 2: subjects with stroke and cognitive dysfunction.
Referring to FIGs 1 to 3, in the present embodiment, a near-infrared spectroscopy device 30 was attached to a brain of a subject 20, wherein the near-infrared spectroscopy device 30 had multiple pairs of LED light source 31 with different emission near-infrared wavelengths and a light sensor 32. The light sources 31 was faced onto the forehead of the subject 20 (referring to the positions of Fql and Fq2 shown in FIG. 3), and then the variation of blood oxygen concentration in the left prefrontal lobe and the right prefrontal lobe could be measured and generated a blood oxygen concentration variation signal 33. The blood oxygen concentration variation signal 33 was then transmitted to an operation unit 40 for data storage and analysis through a wired or wireless connection via the light sensor 32, wherein the sampling frequency could be set up to 50 Hz.
In this embodiment, the LED light sources 31 were three pairs, and each pair of LED light sources 31 could emit two different wavelengths of near-infrared light. In human tissues, light with the wavelength from 650 nm to 950 nm is mainly absorbed by oxygenated hemoglobin and hypoxemic hemoglobin in the blood. In this embodiment, 760 nm and 850 nm wavelengths were used respectively, and the distance between the three pairs of the LED light sources 31 and the light sensors 32 were respectively 30 mm, 35 mm, and 40 mm from the inside to the outside.
The examination process was divided into three phases: 1. Rest phase: The subject 20 was required to close his/her eyes and relax for 1 minute as a reference value in blood oxygen variation.
2. Test stage: The subject 20 was stimulated by a stimulus source 10, wherein the test time varies depending on the subject and the stimulus source.
3. Recovery phase: The subject 20 was required to close his eyes again and relax for
2 minutes to complete the test.
The value of the blood oxygen concentration variation of each subject 20 was the blood oxygen concentration value in the test phase minus the blood oxygen concentration value in the rest phase, and the blood oxygen concentration variations in the left prefrontal lobe and the right prefrontal lobe were all recorded.
Referring to Fig. 4, the concentration of the oxygenated blood was increased in subjects regardless of whether who have had a stroke or cognitive dysfunction.
Referring to FIG. 5, the subjects with normal cognitive function (referred to as the control group 1) had increased oxygen consumption in the brain when stimulated, but the concentrations of hypoxic blood in both the left and right prefrontal lobes were still decreased due to the increased blood supply in reaction to the stimuli. In contrast, in the experimental group 1 and the experimental group 2 (the subjects with cognitive dysfunction), the concentrations of hypoxic blood in both the left and right prefrontal lobes were all increased. It is due to insufficient amount of the reactive blood supply increased to meet the need by stimuli.
The control group 2 in FIG. 5 was the subjects who had stroke but with normal cognitive function via the mini-mental state examination. In this condition, the concentration of hypoxic blood was still decreased in one of the prefrontal lobes, i.e. the increased blood supply in reaction to the stimuli remained normal in at least one of the prefrontal lobes.
Further, the device could be used to evaluate the concentration variation of the oxygenated blood and the hypoxic blood in the left and right prefrontal lobes after stimulation of the subject's brain, and various parameters derived therefrom as diagnostic indicators of whether the subjects have cognitive dysfunction, and for the early detection and early treatment.
Example 2
Referring to FIGs 1 to 3, a marker and a method for elevating cognitive dysfunction of the present invention included: the stimulus 10, the near-infrared spectroscopy device 30, and the operation unit 40 for receiving and calculating the signal from the near-infrared spectroscopy device 30.
The method for evaluating cognitive dysfunction of the present invention comprised the following steps:
Step 1 : Attaching the near-infrared spectroscopy device 30 to the subject's forehead
20;
Step 2: Stimulating the subject 20 via the stimulus 10 for testing cognitive dysfunction, wherein the stimulus 10 was the Wisconsin card sorting test (WCST) in this embodiment. At this time, the near-infrared spectroscopy device 30 was used to detect the concentration of blood oxygen in the prefrontal lobe of the subject, and then produces a blood oxygen variation signal 33 from the prefrontal lobe; Step 3: The operation unit 40 received the blood oxygen variation signal 33 detected by the near-infrared spectroscopy device 30, and then quantizes the signal according to the concentration of oxygenated blood and hypoxic blood as a result report 50;
Step 4: The concentration of oxygenated blood in the result report 50 as control group. When the concentration of oxygenated blood was increased, it indicated that the operation was normal. After then, the concentration of hypoxic blood in both the left and the right prefrontal lobes were all increased, the subject was judged to suffer cognitive dysfunction (referred to FIGs 4 and 5).
The above descriptions are merely preferred embodiments of the present invention, and the scope of the present invention can not be limited thereto; therefore, any simple equivalent changes and modifications made according to the scope of the present invention and the contents of the invention's description all should still fall within the scope of the patent of the present invention.

Claims

WHAT IS CLAIMED IS:
1. A method for evaluating cognitive dysfunction comprising following steps:
Step 1 : Attaching a near-infrared spectroscopy device to a subject's prefrontal lobe to detect blood oxygenation;
Step 2: Relaxing the subject as a reference value in blood oxygen variation;
Step 3: Conducting a stimulus on the brain of the subject;
Step 4: Relaxing the subject again, and blood oxygen variation signals of the prefrontal lobe detected via the near-infrared spectroscopy device are transmitted to an operation unit; and,
Step 5: Analyzing the concentration variation of the oxygenated blood and the hypoxic blood in the left and right prefrontal lobes to a result report to evaluate whether the subject suffers cognitive dysfunction.
2. The method for evaluating cognitive dysfunction of claim 1, wherein the concentration of the oxygenated blood and the hypoxic blood in both the left and right prefrontal lobes of the subject in the result report are all increasing, which means the subject suffers cognitive dysfunction.
3. The method for evaluating cognitive dysfunction of claim 1, wherein the near-infrared spectroscopy device has multiple pairs of LED light source with different emission near-infrared wavelengths and a light sensor, and the values of the concentration variation of the oxygenated blood and the hypoxic blood detected via infrared ray of the LED light source are transmitted to an operation unit.
4. The method for evaluating cognitive dysfunction of claim 3, wherein each pair of LED light sources emits two different wavelengths of near-infrared light, the wavelengths are respectively 760 nm and 850 nm.
5. The method for evaluating cognitive dysfunction of claim 4, wherein the distance between the three pairs of the LED light sources and the light sensors are respectively 30 mm, 35 mm, and 40 mm from the inside to the outside.
6. A marker for evaluating cognitive dysfunction, wherein the marker is that the concentration of the oxygenated blood and the hypoxic blood in both the left and right prefrontal lobes of the subject are all increasing after stimulation, for judging that the subject suffers cognitive dysfunction.
7. The marker for evaluating cognitive dysfunction of claim 6, wherein the marker comprises following steps:
Step 1 : Attaching a near-infrared spectroscopy device to a subject's prefrontal lobe to detect blood oxygenation;
Step 2: Relaxing the subject as a reference value for blood oxygen concentration; Step 3: Conducting a stimulus on the brain of the subject;
Step 4: Relaxing the subject again, and blood oxygen variation signals of the prefrontal lobe detected via the near-infrared spectroscopy device are transmitted to an operation unit; and,
Step 5: Analyzing the concentration of oxygenated blood and hypoxic blood of the left and right prefrontal lobes to a result report to evaluate whether the subject suffers cognitive dysfunction.
8. The method for evaluating cognitive dysfunction of claim 7, wherein the near-infrared spectroscopy device has multiple pairs of LED light source with different emission near-infrared wavelengths and a light sensor, and the values of the concentration variation of the oxygenated blood and the hypoxic blood detected via infrared ray of the LED light source are transmitted to an operation unit.
9. The method for evaluating cognitive dysfunction of claim 8, wherein each pair of
LED light sources emits two different wavelengths of near-infrared light, the wavelengths are respectively 760 nm and 850 nm.
10. The method for evaluating cognitive dysfunction of claim 9, wherein the distance between the three pairs of the LED light sources and the light sensors are respectively 30 mm, 35 mm, and 40 mm from the inside to the outside.
PCT/US2018/035224 2018-05-30 2018-05-30 Marker and method for evaluating cognitive dysfunction WO2019231443A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2018/035224 WO2019231443A1 (en) 2018-05-30 2018-05-30 Marker and method for evaluating cognitive dysfunction

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2018/035224 WO2019231443A1 (en) 2018-05-30 2018-05-30 Marker and method for evaluating cognitive dysfunction

Publications (1)

Publication Number Publication Date
WO2019231443A1 true WO2019231443A1 (en) 2019-12-05

Family

ID=68698429

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/035224 WO2019231443A1 (en) 2018-05-30 2018-05-30 Marker and method for evaluating cognitive dysfunction

Country Status (1)

Country Link
WO (1) WO2019231443A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111956245A (en) * 2020-08-27 2020-11-20 复旦大学附属肿瘤医院 Postoperative cognitive dysfunction prevention and evaluation method, system and device
CN113288174A (en) * 2021-05-31 2021-08-24 中国科学院西安光学精密机械研究所 Method for detecting cognitive function of schizophrenic patient
CN116058801A (en) * 2023-03-06 2023-05-05 慧创科仪(北京)科技有限公司 Evaluation device, evaluation system, and medium for brain function status of autistic children
CN117243569A (en) * 2023-10-12 2023-12-19 国家康复辅具研究中心 Cognitive function assessment method and system based on multi-source information fusion
CN117796811A (en) * 2024-02-29 2024-04-02 中国人民解放军总医院第一医学中心 Assessment method and system for cognitive function in low-oxygen environment

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6498942B1 (en) * 1999-08-06 2002-12-24 The University Of Texas System Optoacoustic monitoring of blood oxygenation
US20040054290A1 (en) * 1995-01-03 2004-03-18 Britton Chance Spectrophotometer for in vivo examination of biological tissue
US20140046170A1 (en) * 2012-08-07 2014-02-13 Chia-Wei Sun Brain volumetric measuring method and system using the same
US20160345880A1 (en) * 2014-01-14 2016-12-01 Haruo Nakaji Near-infrared spectroscopy and diffuse correlation spectroscopy device and methods
US9848812B1 (en) * 2013-07-19 2017-12-26 The United States Of America As Represented By The Administrator Of National Aeronautics And Space Administration Detection of mental state and reduction of artifacts using functional near infrared spectroscopy (FNIRS)
US20180042537A1 (en) * 2015-03-03 2018-02-15 Institute Of Automation Chinese Academy Of Sciences Wireless Wearable Brain Blood-Oxygen Monitoring System

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040054290A1 (en) * 1995-01-03 2004-03-18 Britton Chance Spectrophotometer for in vivo examination of biological tissue
US6498942B1 (en) * 1999-08-06 2002-12-24 The University Of Texas System Optoacoustic monitoring of blood oxygenation
US20140046170A1 (en) * 2012-08-07 2014-02-13 Chia-Wei Sun Brain volumetric measuring method and system using the same
US9848812B1 (en) * 2013-07-19 2017-12-26 The United States Of America As Represented By The Administrator Of National Aeronautics And Space Administration Detection of mental state and reduction of artifacts using functional near infrared spectroscopy (FNIRS)
US20160345880A1 (en) * 2014-01-14 2016-12-01 Haruo Nakaji Near-infrared spectroscopy and diffuse correlation spectroscopy device and methods
US20180042537A1 (en) * 2015-03-03 2018-02-15 Institute Of Automation Chinese Academy Of Sciences Wireless Wearable Brain Blood-Oxygen Monitoring System

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111956245A (en) * 2020-08-27 2020-11-20 复旦大学附属肿瘤医院 Postoperative cognitive dysfunction prevention and evaluation method, system and device
CN113288174A (en) * 2021-05-31 2021-08-24 中国科学院西安光学精密机械研究所 Method for detecting cognitive function of schizophrenic patient
CN113288174B (en) * 2021-05-31 2022-08-19 中国科学院西安光学精密机械研究所 Method for detecting cognitive function of schizophrenic patient
CN116058801A (en) * 2023-03-06 2023-05-05 慧创科仪(北京)科技有限公司 Evaluation device, evaluation system, and medium for brain function status of autistic children
CN116058801B (en) * 2023-03-06 2023-11-10 慧创科仪(北京)科技有限公司 Evaluation device, evaluation system, and medium for brain function status of autistic children
CN117243569A (en) * 2023-10-12 2023-12-19 国家康复辅具研究中心 Cognitive function assessment method and system based on multi-source information fusion
CN117243569B (en) * 2023-10-12 2024-05-07 国家康复辅具研究中心 Cognitive function assessment method and system based on multi-source information fusion
CN117796811A (en) * 2024-02-29 2024-04-02 中国人民解放军总医院第一医学中心 Assessment method and system for cognitive function in low-oxygen environment

Similar Documents

Publication Publication Date Title
WO2019231443A1 (en) Marker and method for evaluating cognitive dysfunction
US10463286B2 (en) Determination of tissue oxygenation in vivo
Schultz et al. Cardiorespiratory fitness attenuates the influence of amyloid on cognition
CN108366737B (en) Optical physiological sensor and method
IL260295B2 (en) Device, system and method for non-invasive monitoring of physiological measurements
WO2003010510A2 (en) Adjunct quantitative system and method for non-invasive measurement of in vivo analytes
US20090171195A1 (en) Functional imaging of autoregulation
Xu et al. Classification of autism spectrum disorder based on sample entropy of spontaneous functional near infra-red spectroscopy signal
US20150217056A1 (en) Therapy systems and methods utilizing tissue oxygenation detection
Warkentin et al. rCBF pathology in Alzheimer's disease is associated with slow processing speed
Nguyen et al. Non-invasive transabdominal measurement of placental oxygenation: a step toward continuous monitoring
Molinari et al. Empirical mode decomposition analysis of near-infrared spectroscopy muscular signals to assess the effect of physical activity in type 2 diabetic patients
JP2000262480A (en) Homeostasis maintenance evaluation device
TW201938109A (en) Biological marker and method for evaluating mild cognitive impairment based on changes of the blood oxygen concentration of the frontal lobe
CN112806992B (en) Tissue oxygen saturation monitoring system and method of self-adaptive spatial resolution spectrum
Du-Yan et al. Convolutional neural network is a good technique for sleep staging based on HRV: A comparative analysis
Giacino Rehabilitation of patients with disorders of consciousness
Wen et al. Comprehensive investigations of cerebral hemodynamic responses in CSVD patients with mental disorders: a pilot study
Olaetxea et al. Photonic Technology for In Vivo Monitoring of Hypoxia–Ischemia
Rakhshani Fatmehsari Designing and Implementing a Portable Near-Infrared Imaging System for Monitoring of Human’s Functional Brain Activity
Yang et al. Comparative study of brain functional imaging of brain in patients with mild to moderate Alzheimer's disease based on functional near infrared spectroscopy
Aziz A Smartphone-Based Non-Invasive Measurement System for Blood Constituents from Photoplethysmography (PPG) and Fingertip Videos Illuminated with the Near-Infrared LEDs
Macnab et al. Monitoring physiologic change in the bladder in health and disease. A new biomedical application of near-infrared spectroscopy
Oni Multimodal fNIRS-EEG Neuroimaging To Monitor Mild Traumatic Brain Injury
Zhang et al. Association of exercise with better olfactory performance and higher functional connectivity between the olfactory cortex and the prefrontal cortex: a resting-state fNIRS study

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18920860

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18920860

Country of ref document: EP

Kind code of ref document: A1